Daratumumab targeting CD38 can lyse lymphoma cells or CD38+ immunosuppressive cells through Fc-mediated complement-dependent cytotoxicity (CDC), ADCC, and Ab-dependent cellular phagocytosis (ADCP) (94). Here, CD38 is linked to lymphoma.